1482. Microbiological Analysis from a Phase II Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections

BACKGROUND: Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits bacterial replication and has in vitro activity against key pathogens, including drug-resistant strains, associated with a range of infections. METHODS: This phase IIa single-center...

Descripción completa

Detalles Bibliográficos
Autores principales: Scangarella-Oman, Nicole, Hossain, Mohammad, Tiemeyer Jr., Timothy, Perry, Caroline R, Tiffany, Courtney, Raychaudhuri, Aparna, Dumont, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808788/
http://dx.doi.org/10.1093/ofid/ofz360.1346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808788/
http://dx.doi.org/10.1093/ofid/ofz360.1346

Ejemplares similares